Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature

Figures & data

Table 1 Studies Examining Treatments for Cutaneous Lupus Erythematosus

First Author (Year)	Type of Study	Treatment	Outcome
Topical Therapy
Presto (2018)^Citation10	RCT	Topical R333 6% (janus kinase and spleen tyrosine kinase inhibitor) vs placebo twice daily for 4 weeks	Four weeks of R333 treatment did not result in significant improvement in lesion activity.
JAK Inhibitors
You (2019)^Citation11	Retrospective	Tofacitinib 5mg BID	Out of 10 patients: 7 patients achieved clinical remission, one patient was relieved with a decreased SLE Disease Activity Index 2000 (SLEDAI-2K) and physician’s global assessment (PGA) score but not clinical remission, one did not improve, and one experienced a flare during the follow-up. Four patients quickly achieved resolution of arthritis and six patients of rash (SLEDAI-2K), respectively. However, the effectiveness of tofacitinib in rash was uncertain in two patients and completely lack of efficacy in another patient. Both SLEDAI-2K (p=0.011) and PGA (p=0.042) were improved significantly at the third month. No significant serological improvement was observed in level of C3 (p=0.319) and anti-dsDNA (p=0.259) at the third month.
Chen (2021)^Citation12	Case report	Tofacitinib 5mg BID	A 29-year-old female SLE patient with a 10-year history of refractory severe diffuse non-scarring alopecia who experienced dramatic hair regrowth with tofacitinib. Prominent hair regrowth on the scalp was observed after 4 weeks, without any rash.
Wenzel (2016)^Citation13	Case report	Ruxolitinib 20mg BID	A 69-year-old female with erythrosquamous skin lesions with acral distribution secondary to chilblain lupus erythematosus. Resulted in complete remission of all lesions within 4 months.
Kreuter (2021)^Citation14	Case report	Baricitinib 4mg daily for 2 months, then ongoing 2mg daily maintenance	A 62-year-old woman with a 4-year history of FFA and SCLE resistant to several previous medications including chloroquine, hydroxychloroquine, methotrexate, azathioprine and rituximab. Resulted in complete clearance of SCLE and stopped further progression of FFA.
Zimmermann (2018)^Citation15	Case series	Baricitinib 4mg daily for 3 months	All patients received a diagnosis of FCL with onset in early childhood. Patient 1 was a woman in her 20s with FCL. Patient 2 was a man in his 70s, and patient 3 was a woman in her 50s. All 3 patients (2 females and 1 male) showed significant improvement of cutaneous lupus lesions.
Joos (2021)^Citation16	Case report	Baricitinib 4mg daily for 6 months	A 54-year-old man presented with a severe progressing widespread rash affecting predominantly trunk and extremities secondary to SCLE. Improvement in CLASI from 21 at baseline to 3 after 6 months of baricitinib treatment.
Fornaro (2019)^Citation17	Case report	Baricitinib 4mg daily for 4 weeks	A 49-year-old SLE female with papulosquamous subacute lesions. Baricitinib 4 mg daily was started and after 4 weeks with near complete resolution of active skin lesions, and, for the first time, the patient was able to stop glucocorticoids.
Maeshima (2020)^Citation18	Case report	Baricitinib 4 mg daily along with prednisolone, mycophenolate mofetil and hydroxychloroquine	A 27-year-old Japanese woman who was diagnosed with SLE at age 21, requiring corticosteroid and tacrolimus treatment. No progression of hair loss was observed after 4 weeks of treatment, and prominent hair regrowth was observed after 8 weeks. At 12 weeks, the prednisolone dose was gradually reduced to 12.5 mg, and no lesions—including alopecia—relapsed.
PDE-4 Inhibitor
De Souza (2012)^Citation19	Prospective	Apremilast 30 mg BID	CLASI showed a significant (P<0.05) decrease after 85 days of treatment in 8 patients with active DLE.
Biologic Therapy
Mazgaj (2020)^Citation20	Case report	Ustekinumab 45 mg SC at weeks 0, 4, then every 12 weeks	A 65-year-old patient with SCLE and psoriasis. The patient reported only partial remission of psoriatic plaques with ustekinumab 45 mg, hence the dose was increased to 90 mg every 8 weeks, leading to long-term resolution of both psoriasis and CLE with excellent tolerance.
Dahl (2013)^Citation21	Case report	Ustekinumab 45mg SC at 0, 4, 16, and 34 wks	A 79-year-old woman presenting with persistent CLE. Using the CLASI scoring system, prior to treatment, the disease activity score was 23, the damage score was 19 and the VAS score was 10. After 34 weeks, the disease activity score decreased to 14, the damage score was unchanged and the VAS score was 5. Objectively, the erythema on the patient’s face, scalp and fingers were improved and the ulcers on her fingertips were healed. The erythema on her toes was unchanged. The patient reported feeling better than she had for many years.
van Vollenhoven (2020)^Citation23	RCT	Ustekinumab (~6 mg/kg single IV infusion, then 90 mg SC every 8 weeks) vs placebo, with standard-of-care therapy	At week 112, 79% and 92% of patients in the ustekinumab and placebo groups, respectively, had an SRI-4 response, 92% in both groups had ≥4-point improvement from baseline in SLEDAI-2K score, 79% and 93%, respectively, had ≥30% improvement from baseline in PGA, 86% and 91%, respectively, had ≥50% improvement in active joint (pain and inflammation) count, and 79% and 100%, respectively, had ≥50% improvement in CLASI activity score.
Ismail (2019)^Citation24	Case report	Tildrakizumab 100 mg SC at weeks 0, 4, and 16	A 39-year-old man with a 15-year history of treatment-resistant lupus erythematosus tumidus. After two doses of tildrakizumab, there was significant improvement in the facial plaques. The response was sustained at week 24.
Merrill (2018)^Citation25	Post hoc analysis	Anifrolumab 300 mg SC every 4 weeks	More anifrolumab-treated patients demonstrated resolution of rash by SLEDAI-2K versus placebo: 39/88 (44.3%) versus 13/88 (14.8%), OR (90% CI) 4.56 (2.48 to 8.39), p<0.001; BILAG: 48/82 (58.5%) versus 24/85 (28.2%), OR (90% CI) 3.59 (2.08 to 6.19), p<0.001; and ≥50% improvement by mCLASI: 57/92 (62.0%) versus 30/89 (33.7%), OR (90% CI) 3.31 (1.97 to 5.55), p<0.001.
Morand (2019)^Citation26	RCT	Anifrolumab (300 mg) SC vs placebo every 4 weeks for 48 weeks	The percentage of patients who had a BILAG-based BICLA response was 47.8% in the anifrolumab group and 31.5% in the placebo group (difference, 16.3 percentage points; 95% confidence interval, 6.3 to 26.3; P = 0.001). Among patients with a high IFN gene signature, the percentage with a response was 48.0% in the anifrolumab group and 30.7% in the placebo group; among patients with a low IFN gene signature, the percentage was 46.7% and 35.5%, respectively.
Furie (2019)^Citation27	RCT	Single dose of BIIB059 SC (humanized IgG1 mAb) ranging from 0.05 mg/kg to 20 mg/kg	BIIB059 administration in patients with SLE decreased expression of IFN response genes in blood, normalized MxA expression, reduced immune infiltrates in skin lesions, and decreased CLASI-A score.
Werth (2017)^Citation28	RCT	Single dose AMG 811 SC180 mg (anti-IFNγ antibody) vs placebo	AMG 811 treatment reduced the IGBS score (which was elevated in DLE patients at baseline) in both the blood and lesional skin. The keratinocyte IFNγ RNA score was not affected by administration of AMG 811. Serum CXCL10 protein levels (which were elevated in the blood of DLE patients) were reduced with AMG 811 treatment. The AMG 811 treatment was well tolerated but did not lead to statistically significant improvements in any of the efficacy outcome measures.

Abbreviations: SLE, Systemic Lupus Erythematosus; CLE, Cutaneous Lupus Erythematosus; SCLE, Subacute Cutaneous Lupus Erythematosus; DLE, Discoid Lupus Erythematosus; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; FFA, Frontal Fibrosing Alopecia; SLEDAI-2K, SLE Disease Activity Index 2000; PGA, Physician’s Global Assessment; VAS, Visual Analog Scale; SRI-4, SLEDAI-2K Responder Index-4; BILAG, British Isles Lupus Assessment Group; mCLASI, Modified Cutaneous Lupus Erythematosus Disease Area and Severity Index; BICLA, British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment; IFN, Interferon; IGBS, IFNγ Blockade Signature; BID, Twice daily; IV, Intravenous; SC, Subcutaneous; mAb, Monoclonal Antibody; OR, Odds Ratio; CI, Confidence Interval; SD, Standard Deviation; MxA, Myxovirus Resistance Gene A; CXCL10, C-X-C motif chemokine ligand 10; FCL, Familial Chilblain Lupus.

Table 2 Studies Examining Treatments for Dermatomyositis

First Author (Year)	Type of Study	Treatment	Outcome
PDE-4 inhibitor
Bitar (2019)^Citation52	Case series	Apremilast 30 mg BID for 3 months	Patient 1. 57-year-old female with DM with heliotrope sign, V-sign with poikiloderma over chest, shawl sign on back: CDASI improved from 43 to 0 after 3 months of treatment Patient 2. 64-year-old female with DM complicated by calcinosis cutis with heliotrope sign, erythematous patches and papules, V-sign with poikiloderma, scalp pruritus, and scale: CDASI improved from 41 to 7 after 3 months of treatment Patient 3. 62-year-old female with DM with heliotrope rash, diffuse violaceous plaques with crusting and ulceration, and periorbital edema: CDASI improved from 62 to 18 after 3 months of treatment
Charlton (2019)^Citation53	Case report	Apremilast 30 mg BID for 3 months	A woman in her 50s with refractory cutaneous dermatomyositis with severe scalp pruritus After 3 months of treatment, she experienced resolution of her heliotrope rash, facial erythema, refractory scalp rash, and pruritus. She also had significant improvement of Gottron’s sign over the extensor aspects of her elbows, but continued to have minimal erythema
Konishi (2021)^Citation51	Prospective open label trial	Apremilast 30 mg BID for 3 months	Patient 1. 71-year-old female with DM Patient 2. 65-year-old female with DM Patient 3. 64-year-old female with DM Patient 4. 39-year-old female with DM Patient 5. 37-year-old female with clinically amyopathic DM Patients 4 and 5 withdrew from study. However, when analyzing the remaining three patients, median CDASI score decreased 30.8 after 12 weeks.
JAK inhibitors
Hornung (2014)^Citation42	Case report	Ruxolitinib 5 mg BID during months 0–2 15 mg BID from months 2–12 10 mg BID from months 13+	A 72-year-old female with refractory DM with periorbital erythema and rash in sun exposed areas. After 12 months of treatment, CDASI improved from 30 to 0.
Le Voyer (2021)^Citation43	Retrospective review	Ruxolitinib for at least 6 months Patient 1: 15 mg BID Patient 2: 10 mg BID Patient 3: 10 mg BID Patient 6: 7.5 mg BID Patient 7: 20 mg BID Patient 8: 10 mg BID Patient 10: 0.7 mg/kg/d Baricitinib for at least 6 months Patient 4: 2 mg BID Patient 5: 4 mg BID Patient 9: 4 mg BID	Ruxolitinib Patient 1. 13-year-old female with DM: Skin DAS score reduced from 4/9 to 0/9 in 2.6 months. Patient 2. 8-year-old female with DM: Skin DAS score reduced from 8/9 to 0/9 in 5.3 months Patient 3. 10-year-old female with DM: Skin DAS score reduced from 2/9 to 0/9 in 5 months Patient 6. 7-year-old female with DM: Skin DAS score reduced from 7/9 to 0/9 in 3 months Patient 7. 12-year-old male with DM: Skin DAS score reduced from 8/9 to 4/9 in 3 months Patient 8. 11-year-old female with DM: Skin DAS score reduced from 8/9 to 0/9 after 3 months. Patient 10. 3-year-old male with DM: Skin DAS score reduced from 8/9 to 0/9 after 3 months. Baricitinib Patient 4. 12-year-old female with DM: Skin DAS score reduced from 3/9 to 0/9 after 1.7 months Patient 5. 5-year-old female with DM: Skin DAS score reduced from 6/9 to 0/9 after 5 months. Patient 9: 9.5-year-old male with DM: Skin DAS score initially 6/8 with no response after 3 months.
Heinen (2020)^Citation44	Case report	Ruxolitinib 30 mg daily for 170 days	A 14-year-old male with juvenile DM with diffuse moderate erythema and palate telangiectasia continued long-term ruxolitinib therapy due to initial clinical improvement on medication after 3 months. On day 170, the sternal rash had diminished, leaving a pale scar-like area
Aeschlimann (2018)^Citation45	Case report	Ruxolitinib 10 mg BID for 10 months	A 13-year-old female with severe vasculopathic refractory juvenile DM with diffuse moderate erythema and palate telangiectasia. Skin DAS improved from 4/9 to 0/9 after 2 months of treatment
Ladislau (2018)^Citation46	Case series	Ruxolitinib 40 mg daily for 3 months	Patient 1. 59-year-old female with DM for 5 years: CDASI improved from 26 to 15 Patient 2. 79-year-old female with DM for 4 years: CDASI improved from 27 to 7 Patient 3. 84-year-old female with DM for 1 year: CDASI improved from 44 to 14 Patient 4. 45-year-old female with DM for 6 years: CDASI improved from 40 to 15
Kurtzman (2016)^Citation29	Case series	Tofacitinib for mean treatment period of 9.6 months. Patient 1: 10 mg BID Patient 2: 5 mg BID Patient 3: 5 mg BID	Patient 1. A female in her 30s with DM for 5 years: CDASI improved from 30 to 14 Patient 2. A female in her 40s with DM for 5 years: CDASI improved from 23 to 10 Patient 3. A female in her 50s with DM for 8 years: CDASI improved from 32 to 25
Moghadam-Kia (2019)^Citation30	Case series	Tofacitinib 5 mg BID for 6 months	Patient 1. 55-year-old female with DM with heliotrope rash, facial erythema, left upper extremity subcutaneous nodules, and inflammatory polyarthropathy: After 3 months of treatment, there was a 50% reduction in facial rash. After 6 months of treatment, she had only minimal erythema over eyelids and subtle facial flushing. Patient 2. 67-year-old female with DM with facial and truncal erythema in addition to inflammatory polyarthropathy: After 3 months of treatment, her facial and truncal erythema persisted but normalized serum muscle enzyme. After 6 months of treatment, she had near resolution of her DM skin rash. Patient 3. 42-year-old male with DM with erythematous rash over forearms, antecubital area, and inflammatory polyarthropathy. After 3 months of treatment, he had 50% skin improvement. After 6 months of treatment, he had continued improvement of his rash. Patient 4. 59-year-old male with DM complicated by discoid lupus with facial and scalp erythema, gottron sign, poikilodermatous changes, and inflammatory arthropathy. After 3 months of treatment, there was a clear improvement in his rash and arthropathy with less pruritus and scaling of his scalp.
Min (2022)^Citation31	Retrospective review	Tofacitinib for mean treatment duration of 27.2 months Patient 1: 10 mg BID Patient 2: 5 mg BID (14 months) and 10 mg BID (10 months) Patient 3: 10 mg BID Patient 4: 5 mg BID (5 months), 10 mg BID (10 months), and 10 mg daily alternating with 10 mg BID (11 months) Patient 5: 10 mg BID Patient 6: 10 mg BID (25 months), and 10 mg daily (3 months) Patient 7: 10 mg BID Patient 8: 5 mg BID (5 months), and 10 mg daily alternating with 20 mg daily (25 months) Patient 9: 10 mg BID Patient 10: 11 mg extended-release daily (21 months), and 11 mg extended-release BID (3 months) Patient 11: 5 mg BID	Patient 1. 31-year-old female with amyopathic DM: CDASI improved from 30 to 14 Patient 2. 50-year-old female with amyopathic DM: CDASI improved from 32 to 10 Patient 3 59-year-old female with amyopathic DM: CDASI improved from 38 to 15 Patient 4 31-year-old male with amyopathic DM: CDASI improved from 27 to 8 Patient 5 54-year-old female with amyopathic DM: CDASI improved from 22 to 7 Patient 6 74-year-old female with classic DM: CDASI improved from 30 to 10 Patient 7 58-year-old female with classic DM: CDASI improved from 17 to 4 Patient 8. 39-year-old female with classic DM: CDASI improved from 23 to 9 Patient 9. 53-year-old female with classic DM: CDASI improved from 26 to 6 Patient 10. 26-year-old female with juvenile DM: CDASI improved from 20 to 9 Patient 11. 19-year-old female with juvenile DM: CDASI improved from 29 to 6
Shneyderman (2021)^Citation32	Case series	Tofacitinib Unspecified dose for 3 months	Patient 1. 50-year-old female with refractory DM for 14 years. There was an improvement in her skin disease after 3 months with an unspecified CDASI score improvement. Patient 2. 55-year-old female with refractory DM for 5 years. There was an improvement in her skin disease after 3 months with an unspecified CDASI score improvement. Patient 3: 35-year-old female with refractory DM for 10 years. There was an improvement in her skin disease after 3 months with an unspecified CDASI score improvement.
Williams (2020)^Citation33	Case report	Tofacitinib 11 mg daily for 6 months	39-year-old woman with DM with facial rash, arthralgias, and worsening lower extremity edema After 6 months of treatment, there was substantial improvement with regained muscle strength, hair regrowth, resolution of her rash, and minimal arthralgias
Paik (2021)^Citation34	Prospective open label study	Tofacitinib 11 mg daily for 12 weeks	10 adult patients 18 years and older with DM. After 12 weeks, there was a statistically significant (p = 0.0005) mean CDASI improvement from 28 ± 15 to 9.5 ± 8.5
Yu (2021)^Citation35	Case series	Tofacitinib 5 mg BID for at least 6 months	Patient 1. 11-year-old female with juvenile DM: Skin DAS improved from 5/9 to 0/9 after 6 months of therapy Patient 2. 10-year-old female with juvenile DM: Skin DAS improved from 2/9 to 0/9 after 6 months of therapy Patient 3. 10-year-old male with juvenile DM: Skin DAS improved from 7/9 to 0/9 after 6 months of therapy
Crespo (2019)^Citation36	Case report	Tofacitinib 5 mg BID for 2 weeks	49-year-old female with DM with itching and localized skin lesions in sun exposed areas After 2 weeks of treatment, all skin lesions and itching improved significantly
Ishikawa Y (2020)^Citation37	Case report	Tofacitinib 10 mg daily for one year	57-year-old female with amyopathic DM complicated by ILD. 6 months after starting treatment, the patient’s skin lesions improved, and ulcerations epithelialized. One year after starting treatment, her prednisone dose was reduced, and disease activity did not re-exacerbate.
Sozeri (2020)^Citation38	Case series	Tofacitinib 5 mg BID for 3 months	Patient 1. 7-year-old male with heliotrope rash, Gottron’s papules, muscle weakness, and skin and muscle calcifications Skin and muscle calcifications completely resolved after 3 months of therapy. Patient 2. 9-year-old female with heliotrope rash, Gottron’s papules, muscle weakness, arthritis, and skin and muscle calcifications: 50% improvement in skin and muscle calcifications after 3 months of therapy
Sabbagh (2019)^Citation39	Case series	Tofacitinib 5 mg BID Patient 1: 6 months Patient 2: 12 months	Patient 1. 12-year-old male with anti-MDA5 autoantibody-positive JDM with malar and heliotrope rashes and Gottron’s papules: CDASI improved from 21 to 12 within 6 months of therapy. Patient 2. 15-year-old female with anti-MDA5 autoantibody-positive JDM with malar rash, digital erythema and ulcers, and hair loss: CDASI improved from 21 to 7 after 1 year of therapy.
Ohmura (2021)^Citation40	Case report	Tofacitinib 5 mg BID for first 25 days 20 mg daily for next 162 days 10 mg daily maintenance afterwards	55-year-old male with Gottron’s signs and itchy confluent macular erythema over upper back, posterior neck, shoulders, and lateral thighs. The patient experienced complete symptom resolution of ulcerating skin lesions after 27 days of treatment. Skin lesions continued to show marked improvement on follow up visits.
Paik (2017)^Citation41	Case report	Tofacitinib 5 mg BID for 6 months during the study and later continued at same dosage for maintenance therapy.	55 year old female with severe, refractory DM with shawl sign, heliotrope rash, Gottron’s papules, periungual erythema, and holster sign. Patient experienced improvement of Gottron’s papules, shawl and V-neck sign, and muscle strength after 2 months of therapy.
Kim (2021)^Citation47	Prospective open label study	Baricitinib 4–8 mg daily (mean 7.25 mg/day) divided two times per day for 24 weeks	4 patients ranging from 5.8 to 20.7 years old with chronically active juvenile DM who had failed 3–6 immunomodulatory medications. There was a statistically significant (p < 0.01) decrease in CDASI scores at the 4, 8, 12, and 24 week timepoints.
Delvino (2020)^Citation48	Case report	Baricitinib 4 mg daily for 3 months	58-year-old female with DM with proximal limb muscle fatigue, facial erythema with swelling of the eyelids and orbits, Gottron’s papules at the metacarpophalangeal joints, oropharyngeal dysphagia for solids and liquids, inflammatory polyarthralgias and high-spiking fever. The patient achieved a rapid and remarkable improvement of her cutaneous lesions, subjective muscle weakness, and polyarthritis after 3 months of treatment
Papadopoulou (2019)^Citation49	Case report	Baricitinib 6 mg BID for 12 months	A 11.5-year-old male of non-consanguineous descent diagnosed with juvenile DM at age 2.5 years with heliotrope rash, gottron’s papules, and proximal muscle weakness. Modified skin DAS improved from 5/5 at baseline to 1/5 after 6 months of treatment. At 12 months of treatment, patient stopped taking all medication against medical advice causing a flare showing modified DAS score returning to 5/5.
Fischer (2022)^Citation50	Case series	Baricitinib 4mg daily Patient 1: 5 months Patient 2: 6 months Patient 3: 4 weeks	Patient 1. Female with 25-year history of recurrent DM with recent cutaneous flare with normal muscle enzymes. Complete resolution of her neck, facial, and periungual erythema occurred after the treatment period. Patient 2. Individual with anti-NXP2 antibody positive DM with severe muscle aches, erythema of the face and abdomen, and DM-related panniculitis of the back. Improvement and gradual resolution of the panniculitis occurred after therapy. Patient 3. Individual with anti-MDA5 antibody positive DM with severe skin involvement and minimal muscle or lung activity. Cutaneous lesions greatly improved in terms of CDASI only after 4 weeks of therapy.
Biologic agents
Xie (2020)^Citation63	Case report	Adalimumab 40 mg weekly for 4 weeks, followed by q2weeks for 12 weeks. Etanercept 50 mg weekly (medication changed due to pregnancy) Adalimumab 40 mg q2weeks for 18 months, then q4weeks for 6 months, then q6weeks for 6 months	24-year-old female with DM and 3 month history of eyelid swelling and a 1-year history of a nonpruritic erythematous rash affecting her chest, face and arms, associated with migraines and with wrist and phalangeal joint pains Patient had an excellent clinical response within 6 months of treatment, with a reduction in symptoms, skin rash, clearing of Gottron’s papules, increase in muscle bulk and strength, and softening and improvement of calcinosis
Campanilho-Marques (2020)^Citation54	Retrospective review	Infliximab 6mg/kg q4weeks alone for 12 months OR Adalimumab 24 mg/m^2 q2weeks alone for 12 months OR Infliximab 6mg/kg q4weeks for mean treatment time of 2.3 months followed by Adalimumab 24 mg/m^2 q2weeks for remaining time until 12 months	60 children with juvenile DM with mean age of onset of 5.2 years old. Infliximab alone: Significant modified skin DAS decrease from 4/5 to 2/5 after 6 months (p = 0.002) and to 1/5 after 12 months (p = 0.0006) of treatment. Adalimumab alone: Statistical analysis limited by low patient number (n = 4) but showed modified skin DAS change from 2/5 to 3/5 at 6 months and 1/5 after 12 months of treatment. Infliximab to Adalimumab: No significant changes in modified skin DAS at 6 months (p = 0.7) or 12 months (p = 0.2) of treatment.
Park (2012)^Citation62	Case report	Adalimumab 40mg q2weeks for 18 doses	48-year-old female with DM with 60 day history of scaled erythematous rash involving the face, elbows, knuckle areas, and proximal muscle weakness. After 18 doses of therapy, skin lesions were improved completely.
Yamada-Kanazawa (2019)^Citation55	Case report	Infliximab 5mg/kg for 1 year	44-year-old female with DM with itchy erythema all over body for 1 month. Skin and joint symptoms improved completely after 1.5 months of treatment.
Huang (2020)^Citation56	Case report	Infliximab 5 mg/kg at weeks 0, 2 and 6, then q8weeks thereafter for an unspecified duration	57-year-old female with DM with eyelid edema, limb weakness, and swallowing difficulties Patient had clinical improvement in rash, muscle pain, and weakness on all subsequent follow up visits.
Chen (2013)^Citation57	Retrospective review	Infliximab 5 mg/kg at weeks 0, 2 and 6, then q8weeks thereafter	14 females with average age 52.57 years old with DM. 10/14 patients had a favorable response, with improved motor strength, reduced rashes, and lung improvement on CT images. The remaining 4 died due of grave respiratory failure.
Riley (2008)^Citation58	Case series	Infliximab 3mg/kg at weeks 0, 2 and 6, then q8weeks thereafter for treatment durations below Patient 1: 24 months Patient 2: 30 months Patient 3: 18 months Patient 4: 12 months Patient 5: 8 months	Patient 1. 8-year-old female with refractory juvenile DM with continuous active muscle and skin disease. VAS improved from 78 to 15 after 24 months. There was a reduction in calcinosis, which was softer and no longer painful. Patient 2. 8-year-old male with juvenile DM with muscle weakness, active skin disease, and painful calcinosis. VAS improved from 41 to 15 after 30 months. Only mild skin disease and calcinosis persisted at the end of treatment Patient 3. 7.5-year-old male with refractory juvenile Dm with muscle weakness, profound lethargy, skin disease, and painful calcinosis. VAS from 24 to 6 after 18 months. Only livedo reticularis remained of his skin disease. Patient 4. 6.5-year-old female with DM with severe facial erythema, moderate muscle weakness, lethargy, and progressive soft calcinosis. VAS remained at 20 after 12 months of treatment. However, patient’s parents noted an improvement in energy levels. Patient 5. 6-year-old female with DM with muscle weakness, severe lethargy, arthralgia, and soft calcinosis: VAS improved from 50 to 40 after 8 months of treatment. The calcified nodules became softer and smaller.
Dold (2007)^Citation59	Case series	Patient 1: Infliximab 5 mg/kg every 2 weeks for three doses Patient 2: Infliximab 3 mg/kg every 2 weeks for three doses	Patient 1. 40-year-old female with DM with symmetric muscle weakness and rash on her face, neck, and metacarpophalangeal joints: After three doses of infliximab, she experienced improved muscle strength and normalized serum CK levels. The patient had a sustained clinical and laboratory response Patient 2. 29-year-old female with proximal symmetric muscle weakness, heliotrope rash, Gottron’s papules, and malar rash involving the nasolabial folds: After three doses of infliximab, her dysphagia resolved; rash became faintly visible, and proximal muscle strength improved.
Hassan (2021)^Citation60	Case report	Infliximab 5 mg/kg at week 0, 2, 6 then q8week thereafter for 3 months	54-year-old female with DM with widespread erythematous rash and generalized weakness After 3 months of treatment, all manifestations improved, including skin rashes, swallowing, and GI vasculopathy.
Roddy (2002)^Citation61	Case report	Infliximab 5mg/kg at 0, 2, and 6 weeks for 3 total doses.	48-year-old female with DM with arthralgia and florid violaceous rash on face and extensor aspects of hands. There was no improvement in this patient’s skin disease.
Rouster-Stevens (2014)^Citation65	Prospective open label study	Etanercept 0.4 mg/kg 2x/week for 12 weeks	Patient 1. 12-year-old female with 7.3-year history of DM: Juvenile DM DAS improved from 14/16 to 13/16 at 24-week follow-up Patient 2. 28-year-old male with 24.6-year history of DM: Juvenile DM DAS score increased from 9/16 to 12/16 at 24-week follow-up Patient 3. 13-year-old female with 4.1-year history of DM: Juvenile DM DAS score improved from 6/16 to 4/16 at 24-week follow-up Patient 4. 7-year-old male with 4.8-year history of DM: Juvenile DM DAS score increased from 10/16 to 13/16 at 24-week follow-up Patient 5. 14-year-old female with 10.8-year history of DM: Juvenile DM DAS score improved from 11/16 to 10/16 at 24-week follow-up Patient 6. 18-year-old female with 3.5-year history of DM: Juvenile DM DAS score improved from 10/16 to 8/16 at 24-week follow-up Patient 7. 14-year-old female with 3.3-year history of DM: Juvenile DM DAS score improved from 14/16 to 13/16 at 24-week follow-up Patient 8. 17-year-old female with 7.2-year history of DM: Juvenile DM DAS score improved from 7/16 to 6/16 at 24-week follow-up
Muscle study group (2011)^Citation64	RCT	Etanercept 50mg weekly (n = 11) or placebo (n = 5) for 24 weeks	Subjects aged 18 to 65 years old with active DM. CDASI score improved from 11.9 to 8.8 but this was not significant (p > 0.05) compared to placebo.
Norman (2006)^Citation66	Case report	Etanercept 25 mg 2x/week for 24 weeks	42-year-old female with DM with violaceous papules over extensor forearms, gottron’s papules, periungual telangiectasias, heliotrope eruption, and poikiloderma over chest, neck, and back. She experienced an excellent clinical response with improvement in both cutaneous and muscle findings after 24 weeks.
Montoya (2017)^Citation67	Case report	Ustekinumab 45 mg given at week 0, week 4, and q12 weeks thereafter for 18 months.	20-year-old male with 5 years of amyopathic DM with erythematous and confluent scaling plaques in multiple skin areas. At 18 month follow up, patient had a very good clinical response, no relapses, and no adverse effects
Kim (2018)^Citation68	Phase 2 double blinded RCT	IMO-8400 0.6 mg/kg, IMO-8400 1.8 mg/kg, or placebo weekly for 24 weeks (IMO-8400 is an oligonucleotide antagonist of TLR7/8/9)	30 subjects with DM with CDASI scores of 15 or greater participated in this study. CDASI score improvement of −9.3 for 0.6 mg/kg, −8.8 for 1.8 mg/kg, and −7.3 for placebo. However, there was no significant difference in CDASI improvement between placebo and treatment groups (p = 0.238)
Cannabinoid receptor agonists
Werth (2022)^Citation69	Phase 2 double blinded RCT	Lenabasum 20mg daily for 28 days, then 20 mg BID for 56 days, or a placebo (Lenabasum is a cannabinoid receptor type 2 agonist)	22 subjects of ≥ 18 years of age with DM and CDASI activity ≥ 14 At day 113, the lenabasum treatment group, compared to the placebo group, had a lower CDASI adjusted least squares mean of 6.5 [SE = 3.1], p = 0.038.

Abbreviations: DM, dermatomyositis; CDASI, cutaneous Dermatomyositis Disease Area and Severity Index; BID, twice daily; QAM, daily every morning; QPM, daily every evening; DAS, skin disease activity score; ILD, idiopathic lung disease; VAS, visual analog score; TLR, toll-like receptor; RCT, randomized controlled trial; SE, standard error.

Presto JK, Okon LG, Feng R, et al. Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus. Br J Dermatol. 2018;178(6):1308–1314. doi:10.1111/bjd.16337

 PubMed Web of Science ®Google Scholar

You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019;78(10):1441–1443. doi:10.1136/annrheumdis-2019-215455

 PubMed Web of Science ®Google Scholar

Chen YL, Liu L-X, Huang Q, et al. Case report: reversal of long-standing refractory diffuse non-scarring alopecia due to systemic lupus erythematosus following treatment with tofacitinib. Front Immunol. 2021;12:654376. doi:10.3389/fimmu.2021.654376

 PubMed Web of Science ®Google Scholar

Wenzel J, van Holt N, Maier J, et al. JAK1/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. J Invest Dermatol. 2016;136(6):1281–1283. doi:10.1016/j.jid.2016.02.015

 PubMed Web of Science ®Google Scholar

Kreuter A, Licciardi‐Fernandez MJ, Burmann S-N, et al. Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia. Clin Exp Dermatol. 2022;47(4):787–788. doi:10.1111/ced.15044

 PubMed Web of Science ®Google Scholar

Zimmermann N, Wolf C, Schwenke R, et al. Assessment of clinical response to janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation. JAMA Dermatol. 2019;155(3):342–346. doi:10.1001/jamadermatol.2018.5077

 PubMed Web of Science ®Google Scholar

Joos L, Vetterli F, Jaeger T, et al. Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib. Clin Exp Dermatol. 2022;47(4):748–750. doi:10.1111/ced.15005

 PubMed Web of Science ®Google Scholar

Fornaro M, Coladonato L, Venerito V, et al. Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. Rheumatology. 2019. doi:10.1093/rheumatology/kez442

 PubMed Web of Science ®Google Scholar

Maeshima K, Shibata H. Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus. Ann Rheum Dis. 2020;79(5):674–675. doi:10.1136/annrheumdis-2019-216571

 PubMed Web of Science ®Google Scholar

De Souza A, Strober BE, Merola JF, Oliver S, Franks AG. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm. pilot study J Drugs Dermatol. 2012;11(10):1224–1226.

 PubMed Web of Science ®Google Scholar

Mazgaj M, Picard‐Dahan C, Deschamps L, et al. Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus. Int J Dermatol. 2020;59(4):e118–e120. doi:10.1111/ijd.14773

 PubMed Web of Science ®Google Scholar

Dahl C, Johansen C, Kragballe K, et al. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm Venereol. 2013;93(3):368–369. doi:10.2340/00015555-1467

 PubMed Web of Science ®Google Scholar

van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. 2020;72(5):761–768. doi:10.1002/art.41179

 PubMed Web of Science ®Google Scholar

Ismail FF, Sinclair RD, Pinczewski J. Refractory lupus erythematosus tumidus responsive to tildrakizumab. Dermatol Ther. 2019;32(5):e13070. doi:10.1111/dth.13070

 PubMed Web of Science ®Google Scholar

Merrill JT, Furie R, Werth VP, et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000284. doi:10.1136/lupus-2018-000284

 PubMed Web of Science ®Google Scholar

Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–221. doi:10.1056/NEJMoa1912196

 PubMed Web of Science ®Google Scholar

Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129(3):1359–1371. doi:10.1172/JCI124466

 PubMed Web of Science ®Google Scholar

Werth VP, Fiorentino D, Sullivan BA, et al. Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-gamma antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol. 2017;69(5):1028–1034. doi:10.1002/art.40052

 PubMed Web of Science ®Google Scholar

Bitar C, Maghfour J, Ho-Pham H, et al. Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients. JAAD Case Rep. 2019;5(2):191–194. doi:10.1016/j.jdcr.2018.11.019

 PubMedGoogle Scholar

Charlton D, Moghadam-Kia S, Smith K, et al. Refractory cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast. J Clin Rheumatol. 2021;27(8S):S561–S562. doi:10.1097/RHU.0000000000000999

 PubMed Web of Science ®Google Scholar

Konishi R, Tanaka R, Inoue S, et al. Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: a phase 1b clinical trial. J Dermatol. 2022;49(1):118–123. doi:10.1111/1346-8138.16179

 PubMed Web of Science ®Google Scholar

Hornung T, Janzen V, Heidgen F-J, et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2014;371(26):2537–2538. doi:10.1056/NEJMc1412997

 PubMed Web of Science ®Google Scholar

Le Voyer T, Gitiaux C, Authier F-J, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology. 2021;60(12):5801–5808. doi:10.1093/rheumatology/keab116

 PubMed Web of Science ®Google Scholar

Heinen A, Schnabel A, Brück N, et al. Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis? Rheumatology. 2021;60(4):e136–e138. doi:10.1093/rheumatology/keaa657

 PubMed Web of Science ®Google Scholar

Aeschlimann FA, Frémond M-L, Duffy D, et al. A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain. 2018;141(11):e80. doi:10.1093/brain/awy255

 PubMed Web of Science ®Google Scholar

Ladislau L, Suárez-Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141(6):1609–1621. doi:10.1093/brain/awy105

 PubMed Web of Science ®Google Scholar

Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152(8):944–945. doi:10.1001/jamadermatol.2016.0866

 PubMed Web of Science ®Google Scholar

Moghadam-Kia S, Charlton D, Aggarwal R, et al. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology. 2019;58(6):1011–1015. doi:10.1093/rheumatology/key366

 PubMed Web of Science ®Google Scholar

Min MS, Alsarheed A, Kassamali B, et al. Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers. J Am Acad Dermatol. 2022;86(2):423–425. doi:10.1016/j.jaad.2021.07.003

 PubMed Web of Science ®Google Scholar

Shneyderman M, Ahlawat S, Christopher-Stine L, et al. Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series. Rheumatology. 2021;60(11):e387–e388. doi:10.1093/rheumatology/keab421

 PubMed Web of Science ®Google Scholar

Williams P, McKinney B. Refractory dermatomyositis-systemic lupus erythematosus overlap syndrome and response to tofacitinib. Proc (Bayl Univ Med Cent). 2020;34(1):116–117. doi:10.1080/08998280.2020.1821589

 PubMedGoogle Scholar

Paik JJ, Casciola‐Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol. 2021;73(5):858–865. doi:10.1002/art.41602

 PubMed Web of Science ®Google Scholar

Yu Z, Wang L, Quan M, et al. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Rheumatology. 2021;60(4):1700–1707. doi:10.1093/rheumatology/keaa558

 PubMed Web of Science ®Google Scholar

Crespo Cruz A, Del Boz J, Romero Gomez C. Good response to tofacitinib in refractory amyopathic dermatomyositis. Actas Dermosifiliogr. 2021;112(4):374–376. doi:10.1016/j.ad.2019.07.016

 PubMed Web of Science ®Google Scholar

Ishikawa Y, Kasuya T, Fujiwara M, et al. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report. Medicine. 2020;99(37):e21943. doi:10.1097/MD.0000000000021943

 PubMed Web of Science ®Google Scholar

Sozeri B, Demir F. A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate. Rheumatology. 2020;59(12):e140–e141. doi:10.1093/rheumatology/keaa360

 PubMed Web of Science ®Google Scholar

Sabbagh S, Almeida de Jesus A, Hwang S, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59. doi:10.1093/brain/awz293

 PubMed Web of Science ®Google Scholar

Ohmura SI, Yamabe T, Naniwa T. Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies. Mod Rheumatol Case Rep. 2021;5(1):76–81. doi:10.1080/24725625.2020.1816674

 PubMedGoogle Scholar

Paik JJ, Christopher-Stine L. A case of refractory dermatomyositis responsive to tofacitinib. Semin Arthritis Rheum. 2017;46(4):e19. doi:10.1016/j.semarthrit.2016.08.009

 PubMedGoogle Scholar

Kim H, Dill S, O’Brien M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2021;80(3):406–408. doi:10.1136/annrheumdis-2020-218690

 PubMed Web of Science ®Google Scholar

Delvino P, Bartoletti A, Monti S, et al. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis. Rheumatology. 2020;59(12):e125–e127. doi:10.1093/rheumatology/keaa184

 PubMed Web of Science ®Google Scholar

Papadopoulou C, Hong Y, Omoyinmi E, et al. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain. 2019;142(3):e8. doi:10.1093/brain/awz005

 PubMed Web of Science ®Google Scholar

Fischer K, Aringer M, Steininger J, et al. Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib. Br J Dermatol. 2022;187:432–435. doi:10.1111/bjd.21252

 PubMed Web of Science ®Google Scholar

Xie F, Williams P, Batchelor R, et al. Successful treatment of dermatomyositis and associated calcinosis with Adalimumab. Clin Exp Dermatol. 2020;45(7):945–949. doi:10.1111/ced.14325

 PubMed Web of Science ®Google Scholar

Campanilho-Marques R, Deakin CT, Simou S, et al. Retrospective analysis of infliximab and Adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther. 2020;22(1):79. doi:10.1186/s13075-020-02164-5

 PubMed Web of Science ®Google Scholar

Park JK, Yoo H-G, Ahn D-S, et al. Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with Adalimumab. Rheumatol Int. 2012;32(11):3587–3590. doi:10.1007/s00296-011-2220-4

 PubMed Web of Science ®Google Scholar

Yamada-Kanazawa S, Kajihara I, Kobayashi A, et al. Infliximab improved the refractory cutaneous involvement in a patient with dermatomyositis. Dermatol Ther. 2019;32(3):e12859. doi:10.1111/dth.12859

 PubMed Web of Science ®Google Scholar

Huang BB, Han L-C, Liu G-F, et al. Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: a case report. World J Gastroenterol. 2020;26(46):7425–7435. doi:10.3748/wjg.v26.i46.7425

 PubMed Web of Science ®Google Scholar

Chen D, Wang X-B, Zhou Y, et al. Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol Int. 2013;33(10):2455–2458. doi:10.1007/s00296-012-2653-4

 PubMed Web of Science ®Google Scholar

Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology. 2008;47(6):877–880. doi:10.1093/rheumatology/ken074

 PubMed Web of Science ®Google Scholar

Dold S, Justiniano ME, Marquez J, et al. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol. 2007;26(7):1186–1188. doi:10.1007/s10067-006-0325-z

 PubMed Web of Science ®Google Scholar

Hassan N, Davies EJ, Faber BG, et al. Infliximab in a patient with treatment-resistant anti-SAE dermatomyositis. Rheumatology. 2021;60(5):e156–e158. doi:10.1093/rheumatology/keaa698

 PubMed Web of Science ®Google Scholar

Roddy E, Courtney PA, Morris A. Non-Hodgkin’s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology. 2002;41(10):1194–1195. doi:10.1093/rheumatology/41.10.1194

 PubMed Web of Science ®Google Scholar

Rouster-Stevens KA, Ferguson L, Morgan G, et al. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res. 2014;66(5):783–787. doi:10.1002/acr.22198

 PubMed Web of Science ®Google Scholar

Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70(3):427–436. doi:10.1002/ana.22477

 PubMed Web of Science ®Google Scholar

Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol. 2006;54(3 Suppl 2):S139–42. doi:10.1016/j.jaad.2005.11.1090

 PubMed Web of Science ®Google Scholar

Montoya CL, Gonzalez ML, Ospina FE, et al. A rare case of amyopathic juvenile dermatomyositis associated with psoriasis successfully treated with ustekinumab. J Clin Rheumatol. 2017;23(2):129–130. doi:10.1097/RHU.0000000000000430

 PubMed Web of Science ®Google Scholar

Kim HJ, Zeidi M, Bonciani D, et al. Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol. 2018;179(3):669–678. doi:10.1111/bjd.16498

 PubMed Web of Science ®Google Scholar

Werth VP, Hejazi E, Pena SM, et al. Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial. J Invest Dermatol. 2022. doi:10.1016/j.jid.2022.03.029

 Web of Science ®Google Scholar